Search alternatives:
point decrease » point increase (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
20281
Table_1_Impacts of AD-Related ABCA7 and CLU Variants on Default Mode Network Connectivity in Healthy Middle-Age Adults.DOCX
Published 2020“…Objective<p>To investigate the impact of Alzheimer’s disease (AD)-related risk gene (ATP-binding cassette A7-ABCA7 and Clusterin-CLU) on the functional connectivity pattern of default mode network (DMN) in healthy middle-age adults.…”
-
20282
-
20283
FTIR spectra of Gel/MWCNT nanocomposites for various amounts of MWCNT filler content.
Published 2023Subjects: -
20284
-
20285
The complex impedance spectra of the nanocomposites with the fitting curves.
Published 2023Subjects: -
20286
Characteristics of EF1-driven single copy NR1I2, NR4A1, or RORA stably-transfected cells.
Published 2024Subjects: -
20287
Expression of nuclear receptor (NR) genes using dual recombinase-mediated cassette exchange.
Published 2024Subjects: -
20288
-
20289
-
20290
Transcripts per million (TPM) of CMV and EF1, DsRed, and Halo at 2, 4, 6, and 8 weeks.
Published 2024Subjects: -
20291
-
20292
The change in water contact angle of Gel/MWCNT nanocomposites for different concentration of MWCNTs.
Published 2023Subjects: -
20293
The capacitive retention for 5000 cycles of GCD for the Gel/0.05% MWCNT nanocomposite.
Published 2023Subjects: -
20294
-
20295
-
20296
-
20297
-
20298
-
20299
-
20300
Antinociceptive effect of N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide on different pain models in mice
Published 2022“…<div><p>Abstract N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide (DDIAHB) is a new drug developed through molecular modelling and rational drug design by the molecular association of epinastine and salicylic acid. …”